Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Aug:109:91.
doi: 10.1016/j.ijid.2021.06.048. Epub 2021 Jun 24.

Antiviral Effects of Ivermectin in COVID-19- Clinically Plausible?

Dr Ajay Kumar Shukla  1 , Dr Saurav Misra  2
Affiliations
Comment

Antiviral Effects of Ivermectin in COVID-19- Clinically Plausible?

Dr Ajay Kumar Shukla et al. Int J Infect Dis. 2021 Aug.
No abstract available

Keywords: COVID-19, Ivermectin, Anti-viral effect.

PubMed Disclaimer

Comment in

Comment on

References

    1. Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, et al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. Int J Infect Dis. 2021;103:214–216. Feb. - PMC - PubMed
    1. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178 - PMC - PubMed
    1. Camprubí D, Almuedo-Riera A, Martí-Soler H, Soriano A, Hurtado JC, Subirà C, et al. Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients. PLoS One. 2020;15 - PMC - PubMed
    1. Chaccour C, Hammann F, Rabinovich NR. Ivermectin to reduce malaria transmission I. Pharmacokinetic and pharmacodynamic considerations regarding efficacy and safety. Malar J. 2017;16:161. - PMC - PubMed
    1. Guzzo CA, Furtek CI, Porras AG, Chen C, Tipping R, Clineschmidt CM, et al. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J Clin Pharmacol. 2017;42:1122–1133. - PubMed